Enterococcus species, particularly Enterococcus faecium, have become a major nosocomial pathogen due to their ability to resist antibiotics and adapt to hospital environments. These bacteria are Gram-positive, facultatively anaerobic, and can survive in harsh conditions. They are common colonizers of the gastrointestinal tract and have been linked to various infections, including endocarditis. However, their pathogenic potential is often low, as they are naturally present in the gut and have been used as probiotics. The rise of Enterococcus as a nosocomial pathogen is attributed to factors such as antibiotic resistance, the ability to acquire resistance genes, and their malleable genomes. The use of antibiotics in hospitals disrupts the gut microbiota, allowing vancomycin-resistant enterococci (VRE) to proliferate. Enterococci, especially E. faecium, are more resistant to vancomycin and ampicillin than E. faecalis, making them more challenging to treat. The prevalence of VRE has increased globally, with significant outbreaks in Europe and Latin America. Enterococci can survive on environmental surfaces and are resistant to heat, chlorine, and some alcohol. They are transmitted in hospitals through contact with contaminated surfaces and healthcare workers. Risk factors for VRE infections include prolonged hospitalization, immunosuppression, and the use of multiple antibiotics. The population genetics of enterococci show that E. faecium has evolved into a hospital-associated clade with distinct genetic characteristics. The genomes of these bacteria are highly plastic, allowing them to acquire and exchange genetic material, contributing to their adaptability. Enterococci have various virulence factors, including secreted proteins and cell surface determinants, which aid in their pathogenicity. Antibiotic resistance mechanisms in enterococci include the production of penicillin-binding proteins with low affinity for antibiotics, the presence of resistance genes, and the lack of CRISPR elements that provide defense against foreign DNA. The resistance to various antibiotics, including β-lactams, aminoglycosides, and glycopeptides, has made treatment of enterococcal infections challenging. The emergence of multidrug-resistant enterococci has led to the need for new therapeutic strategies. Understanding the mechanisms of resistance and the factors contributing to their rise is crucial for developing effective treatments and preventing the spread of these pathogens in hospitals. Continued research into enterococcal genomics and pathogenesis is essential for addressing the growing challenge of these bacteria as nosocomial pathogens.Enterococcus species, particularly Enterococcus faecium, have become a major nosocomial pathogen due to their ability to resist antibiotics and adapt to hospital environments. These bacteria are Gram-positive, facultatively anaerobic, and can survive in harsh conditions. They are common colonizers of the gastrointestinal tract and have been linked to various infections, including endocarditis. However, their pathogenic potential is often low, as they are naturally present in the gut and have been used as probiotics. The rise of Enterococcus as a nosocomial pathogen is attributed to factors such as antibiotic resistance, the ability to acquire resistance genes, and their malleable genomes. The use of antibiotics in hospitals disrupts the gut microbiota, allowing vancomycin-resistant enterococci (VRE) to proliferate. Enterococci, especially E. faecium, are more resistant to vancomycin and ampicillin than E. faecalis, making them more challenging to treat. The prevalence of VRE has increased globally, with significant outbreaks in Europe and Latin America. Enterococci can survive on environmental surfaces and are resistant to heat, chlorine, and some alcohol. They are transmitted in hospitals through contact with contaminated surfaces and healthcare workers. Risk factors for VRE infections include prolonged hospitalization, immunosuppression, and the use of multiple antibiotics. The population genetics of enterococci show that E. faecium has evolved into a hospital-associated clade with distinct genetic characteristics. The genomes of these bacteria are highly plastic, allowing them to acquire and exchange genetic material, contributing to their adaptability. Enterococci have various virulence factors, including secreted proteins and cell surface determinants, which aid in their pathogenicity. Antibiotic resistance mechanisms in enterococci include the production of penicillin-binding proteins with low affinity for antibiotics, the presence of resistance genes, and the lack of CRISPR elements that provide defense against foreign DNA. The resistance to various antibiotics, including β-lactams, aminoglycosides, and glycopeptides, has made treatment of enterococcal infections challenging. The emergence of multidrug-resistant enterococci has led to the need for new therapeutic strategies. Understanding the mechanisms of resistance and the factors contributing to their rise is crucial for developing effective treatments and preventing the spread of these pathogens in hospitals. Continued research into enterococcal genomics and pathogenesis is essential for addressing the growing challenge of these bacteria as nosocomial pathogens.